| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Luba Greenwood is Director at INAB. Luba Greenwood's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $7K at current prices.
Net of sales, the INAB filings show accumulation of 526 shares.
Luba Greenwood has 10 Form 4 filings on record from July 2021 to May 2026, across 3 companies: Director at IN8bio (INAB), 2021–2026; Traws Pharma (TRAW), 2024; Director at Ernexa Therapeutics (ERNA), 2021.
The 10 reported transactions were 9 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $999 and no sales.
The only open-market purchase was 526 shares of INAB at an average $1.90 on August 16, 2022, about $999. Twelve months later INAB was down 37%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | INAB In8bio, Inc. | Director | Buy | 526 | $1.90 | $999.40 | +7.2% | -19.6% | -37.0% |